IN2012DN00719A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00719A IN2012DN00719A IN719DEN2012A IN2012DN00719A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A IN 719DEN2012 A IN719DEN2012 A IN 719DEN2012A IN 2012DN00719 A IN2012DN00719 A IN 2012DN00719A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disorders
- compositions
- useful
- cftr
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 5
- 102000012605 Cystic Fibrosis Transmembrane Conductance Regulator Human genes 0.000 abstract 4
- 108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000031513 cyst Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000037427 ion transport Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23274109P | 2009-08-10 | 2009-08-10 | |
| PCT/US2010/045052 WO2011019737A1 (en) | 2009-08-10 | 2010-08-10 | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00719A true IN2012DN00719A (enExample) | 2015-06-19 |
Family
ID=43586433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN719DEN2012 IN2012DN00719A (enExample) | 2009-08-10 | 2010-08-10 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8609661B2 (enExample) |
| EP (1) | EP2464354B1 (enExample) |
| CN (1) | CN102695510A (enExample) |
| CA (1) | CA2769847C (enExample) |
| IN (1) | IN2012DN00719A (enExample) |
| WO (1) | WO2011019737A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE48842E1 (en) * | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| AU2013365827A1 (en) | 2012-12-19 | 2015-07-09 | Novartis Ag | Tricyclic compounds as CFTR inhibitors |
| AP2015008539A0 (en) | 2012-12-19 | 2015-06-30 | Novartis Ag | Tricyclic compounds for inhibiting the CFTR channel |
| GB201905711D0 (en) * | 2019-04-24 | 2019-06-05 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| CN114948966B (zh) * | 2022-04-27 | 2023-06-20 | 南京鼓楼医院 | 一种小分子抑制剂在制备治疗多发性硬化和脓毒症的药物中的应用 |
| CN115998763A (zh) * | 2023-01-17 | 2023-04-25 | 暨南大学 | 氯离子及靶向氯离子通道的化合物在调控铁死亡中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2751969B1 (fr) * | 1996-08-01 | 1998-12-04 | Centre Nat Rech Scient | Composes activateurs du canal cftr, et compositions pharmaceutiques les contenant |
| GB9626643D0 (en) * | 1996-12-21 | 1997-02-12 | Astra Pharma Prod | Compounds |
| US7235573B2 (en) | 2002-09-30 | 2007-06-26 | The Regents Of The University Of California | Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| FR2861304B1 (fr) * | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| CA2561560A1 (en) | 2004-03-30 | 2005-10-13 | The Regents Of The University Of California | Hydrazide-containing cftr inhibitor compounds and uses thereof |
| WO2006068928A1 (en) * | 2004-12-20 | 2006-06-29 | Wyeth | Pyrrolo[1,2-a]quinoxalin-5-(4h)-yl)sulfonyls and carbonyls and their use as estrogenic agents |
| CN101668732A (zh) * | 2007-04-02 | 2010-03-10 | 同一世界健康研究院 | Cftr抑制剂化合物及其用途 |
| JP5637859B2 (ja) * | 2007-12-13 | 2014-12-10 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター |
| KR20100134063A (ko) | 2008-03-25 | 2010-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제 |
| CA2718676A1 (en) | 2008-04-04 | 2009-12-03 | The Regents Of The University Of California | Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator |
| USRE48842E1 (en) | 2011-05-27 | 2021-12-07 | The Regents Of The University Of California | Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor |
-
2010
- 2010-08-10 IN IN719DEN2012 patent/IN2012DN00719A/en unknown
- 2010-08-10 EP EP10808643.0A patent/EP2464354B1/en active Active
- 2010-08-10 CN CN2010800427350A patent/CN102695510A/zh active Pending
- 2010-08-10 CA CA2769847A patent/CA2769847C/en active Active
- 2010-08-10 US US13/389,898 patent/US8609661B2/en active Active
- 2010-08-10 WO PCT/US2010/045052 patent/WO2011019737A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769847A1 (en) | 2011-02-17 |
| EP2464354A1 (en) | 2012-06-20 |
| US20120208822A1 (en) | 2012-08-16 |
| CA2769847C (en) | 2019-01-08 |
| EP2464354B1 (en) | 2015-04-01 |
| EP2464354A4 (en) | 2013-03-27 |
| CN102695510A (zh) | 2012-09-26 |
| WO2011019737A1 (en) | 2011-02-17 |
| US8609661B2 (en) | 2013-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2010010343A (es) | Inhibidores solubles en agua de molecula pequeña del regulador de conductancia transmembrana de fibrosis quistica. | |
| IN2012DN00719A (enExample) | ||
| MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
| WO2007129226A3 (en) | Use of syk tyrosine kinase inhibitors for the treatment of cell proliferative disorders | |
| WO2008154251A3 (en) | C3b antibodies and methods for the prevention and treatment of complement- associated disorders | |
| WO2008147797A3 (en) | Ion channel modulators and methods of use | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| TW200604192A (en) | Compounds and methods for inhibiting mitotic progression | |
| WO2006088888A3 (en) | Aptamer therapeutics useful in the treatment of complement-related disorders | |
| MY172151A (en) | Certain chemical entities, compositions and methods | |
| WO2009023509A3 (en) | Therapeutic combinations useful in treating cftr related diseases | |
| WO2008137633A3 (en) | Methods of modulating cellular homeostatic pathways and cellular survival | |
| WO2007064857A8 (en) | Amphoteric liposome formulation | |
| EP3632444A3 (en) | Topical lfa-1 antagonists for use in localized treatment of immune related disorders | |
| EP2134736A4 (en) | FIVE- AND SIX-PIECE CONFORMATIVELY FIXED 2 ', 4'-CARBOCYCLIC RIBOTHYMIDINE FOR THE TREATMENT OF INFECTIONS AND CANCER | |
| EA201071248A1 (ru) | Дизамещенные фталазиновые антагонисты пути hedgehog | |
| WO2008095086A3 (en) | Topiramate plus naltrexone for the treatment of addictive disorders | |
| WO2010009478A3 (en) | Compositions and methods for treating disorders associated with overweight animals | |
| WO2009146144A3 (en) | Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator | |
| IN2012DN02471A (enExample) | ||
| EP2765227A3 (en) | Compositions and methods for identifying autism spectrum disorders | |
| WO2008144223A3 (en) | Triazolyl aminopyrimidine compounds | |
| WO2012158672A3 (en) | Compounds for use in treatment of mucositis | |
| WO2009158374A3 (en) | Inhibitors of akt activity | |
| WO2009009034A3 (en) | Methods and compositions useful in the treatment of mucositis |